Cited 36 times in
A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.